Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 11, 2019

Protagonist doses first patient in Phase II trial of PTG-300

Protagonist Therapeutics has dosed the first patient in a Phase II trial of PTG-300 for the treatment of patients with beta thalassemia.

Protagonist Therapeutics has dosed the first patient in a Phase II trial of PTG-300 for the treatment of patients with beta thalassemia.

Beta thalassemia is a rare disease caused by chronic anemia and iron overload.

The trial aims to study the safety and preliminary efficacy of PTG-300 in around 84 adolescent and adult patients.

It features a global, single-arm, open label, multiple-ascending dose setting.

The studuy will include patients with transfusion-dependent or non-transfusion-dependent beta thalassemia.

“PTG-300 has broad potential in the treatment of other disorders, including hereditary hemochromatosis.”

Non-transfusion-dependent patients will be treated with PTG-300 in ascending dose over a period of 12 weeks, while the transfusion-dependent patients will receive PTG-300 in an escalating dose for 16 weeks.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Primary efficacy objective for the non-transfusion-dependent patients and the transfusion-dependent patients include the change in hemoglobin from baseline and change in transfusion burden from baseline, respectively.

Protagonist Therapeutics president and CEO Dinesh Patel said: “In addition to beta thalassemia, PTG-300 has broad potential in the treatment of other disorders, including hereditary hemochromatosis and the myeloproliferative neoplasms polycythemia vera and myelodysplastic syndrome.

“The Phase II trial incorporates an open-label trial design and we expect to report initial results in the second half of 2019.

“We are actively evaluating additional disease indications for development of PTG-300 and plan to commence on a second indication in the second half of 2019.”

In a closed Phase I trial, PTG-300 was found to be well tolerated as well as showed a dose-related and sustained reduction in serum iron levels among healthy participants.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU